Bridges Jason P, Gilbert Jeffrey S, Colson Drew, Gilbert Sara A, Dukes Matthew P, Ryan Michael J, Granger Joey P
Department of Physiology and the Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Am J Hypertens. 2009 May;22(5):564-8. doi: 10.1038/ajh.2009.24. Epub 2009 Mar 5.
Recent evidence indicates that both increased oxidative stress and an altered balance between pro- and anti-angiogenic factors such as vascular-endothelial growth factor (VEGF) and the soluble VEGF receptor (sFlt-1) contribute to endothelial dysfunction in preeclampsia. We hypothesized that chronic infusion of sFlt-1 to mimic the increase observed in preeclamptic patients would reduce plasma VEGF concentrations, increase blood pressure (BP) and vascular superoxide levels, and cause endothelial dysfunction in the pregnant rat.
Recombinant sFlt-1 was infused (500 ng/h) during days 13-18 of pregnancy. BP, fetal and placental weight, oxidative stress and vessel vasorelaxation were determined on day 18 of pregnancy.
Plasma sFlt-1 concentrations (299 +/- 33 vs. 100 +/- 16 pg/ml; P < 0.01) and BP (117 +/- 6 vs. 98 +/- 4 mm Hg; P < 0.01) were increased, while plasma-free VEGF concentrations (570 +/- 77 vs. 780 +/- 48 pg/ml; P < 0.01) were decreased when compared to vehicle infused dams. sFlt-1 rats had smaller fetuses (1.3 +/- 0.03 vs. 1.5 +/- 0.04 g, P < 0.01) and placentas (0.41 +/- 0.01 vs. 0.47 +/- 0.02 g; P < 0.05). Placental (180 +/- 66 vs. 24 +/- 2.3 RLU/min/mg; P < 0.05) and vascular (34 +/- 8 vs. 12 +/- 5 RLU/min/mg; P < 0.05) superoxide production was increased in the sFlt-1 compared to vehicle infused rats. Vasorelaxation to acetylecholine (ACh) and sodium nitroprusside (SNP) were both decreased (P < 0.05) in the sFlt-1 infusion group compared to the vehicle and this decrease was attenuated (P < 0.05) by the superoxide scavenger Tiron.
These data indicate elevated maternal sFlt-1 and decreased VEGF concentrations results in increased oxidative stress that contributes to vascular dysfunction during pregnancy.
最近的证据表明,氧化应激增加以及促血管生成因子和抗血管生成因子(如血管内皮生长因子(VEGF)和可溶性VEGF受体(sFlt-1))之间平衡的改变,均有助于子痫前期患者的内皮功能障碍。我们假设,长期输注sFlt-1以模拟子痫前期患者中观察到的增加,会降低血浆VEGF浓度,升高血压(BP)和血管超氧化物水平,并导致妊娠大鼠的内皮功能障碍。
在妊娠第13至18天期间输注重组sFlt-1(500 ng/h)。在妊娠第18天测定血压、胎儿和胎盘重量、氧化应激和血管舒张功能。
与输注赋形剂的母鼠相比,sFlt-1组母鼠的血浆sFlt-1浓度(299±33 vs. 100±16 pg/ml;P<0.01)和血压(117±6 vs. 98±4 mmHg;P<0.01)升高,而血浆游离VEGF浓度(570±77 vs. 780±48 pg/ml;P<0.01)降低。sFlt-1组的胎儿(1.3±0.03 vs. 1.5±0.04 g,P<0.01)和胎盘(0.41±0.01 vs. 0.47±0.02 g;P<0.05)较小。与输注赋形剂的大鼠相比,sFlt-1组胎盘(180±66 vs. 24±2.3 RLU/min/mg;P<0.05)和血管(34±8 vs. 12±5 RLU/min/mg;P<0.05)的超氧化物生成增加。与赋形剂组相比,sFlt-1输注组对乙酰胆碱(ACh)和硝普钠(SNP)的血管舒张反应均降低(P<0.05),而超氧化物清除剂替诺则减弱了这种降低(P<0.05)。
这些数据表明,母体sFlt-1升高和VEGF浓度降低导致氧化应激增加,这有助于妊娠期间的血管功能障碍。